Department of Health (DOH) Minister Yaung Chih-liang hailed Wednesday at the Legislative Yuan the mid-term results of human clinical testing of H1N1 vaccine produced by Adimmune Corp, Taiwan's sole human vaccine manufacturer. Fielding questions at a meeting of the legislature's Social Welfare and Environmental Hygiene Committee about the locally produced vaccine, Yaung said the Adimmune vaccine is in no way inferior to an H1N1 vaccine marketed by the Swiss-based pharmaceutical firm Novartis. Stressing that the initial results have been good, Yaung said, however, that the final results will be made public in two days, after related data has been collated by a DOH pharmaceutical screening committee. According to Kang Chao-chou, chief of the DOH's Bureau of Pharmaceutical Affairs, the screening committee was scheduled to meet the following day to review the mid-term results. The relevant data will be published after being confirmed by the committee and conclusions will be submitted to the Centers for Disease Control for reference. A complete report on the efficacy and safety of the Adimmune vaccine is expected to be available in mid-November, Kang said. Meanwhile, Ho Mei-shiang, head of Adimmune's R&D department, told reporters that the immunity effect of the swine flu vaccine is marvelous, as had been expected, and she urged the public not to be worried about any ill-effects. According to Ho, the immunity effect of foreign-made H1N1 vaccines can reach 70 percent, while the mid-term results of the Adimmune vaccine's adult clinical trials show that the local vaccine will not be any lower than that. 